Matsuoka Atsuko
Division of Medical Devices, National Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan.
Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku. 2012(130):13-20.
In the market of medical devices, non-Japanese products hold a large part even in Japan. To overcome this situation, the Japanese government has been announcing policies to encourage the medical devices industry, such as the 5-year strategy for medical innovation (June 6, 2012). The Division of Medical Devices has been contributing to rapid marketing of medical devices by working out the standards for approval review and accreditation of medical devices, guidances on evaluation of medical devices with emerging technology, and test methods for biological safety evaluation of medical devices, as a part of practice in the field of regulatory science. The recent outcomes are 822 standards of accreditation for Class II medical devices, 14 guidances on safety evaluation of medical devices with emerging technology, and the revised test methods for biological safety evaluation (MHLW Notification by Director, OMDE, Yakushokuki-hatsu 0301 No. 20 "Basic Principles of Biological Safety Evaluation Required for Application for Approval to Market Medical Devices").
在医疗器械市场中,即便在日本,非日本产品也占据了很大一部分份额。为改变这种局面,日本政府一直在公布鼓励医疗器械行业发展的政策,比如《医疗创新五年战略》(2012年6月6日)。作为监管科学领域实践的一部分,医疗器械司通过制定医疗器械审批审查和认证标准、新兴技术医疗器械评估指南以及医疗器械生物安全性评估测试方法,为医疗器械的快速上市做出了贡献。近期成果包括822项二类医疗器械认证标准、14份新兴技术医疗器械安全性评估指南以及修订后的生物安全性评估测试方法(厚生劳动省药品医疗器械局局长通知,药械初发0301第20号《医疗器械上市许可申请所需生物安全性评估基本原则》)。